@article {43929,
	title = {Convenient new and efficient commercial synthetic route for dasatinib (sprycel{\textregistered})},
	journal = {Synthetic Communications},
	volume = {47},
	year = {2017},
	month = {JUN},
	pages = {1610-1621},
	type = {Article},
	abstract = {A new and efficient synthetic route for dual Src/Abl kinase inhibitor Dasatinib (Sprycel{\textregistered}), an anticancer drug, is described. This commercially viable process yields Dasatinib monohydrate free of potential impurities with consistent yield of 68\% in route A and 61\% in route B with HPLC purity >99.80\% over 4 stages.},
	doi = {10.1080/00397911.2017.1337150},
	author = {Suresh, Garbapu and Nadh, Ratnakaram Venkata and Srinivasu, Navuluri and Yennity, Durgaprasad}
}
